Evidence map›Paper›PMID 41479888›Full record

ArticleFrontiers in immunology2025

Lymphocyte dynamics as the central mediator in osimertinib-induced CD4

Liya Zhu, Dan Liu, Jie Peng, Jinzhi Lu

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Liya Zhu *Department of Infectious Diseases, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
Dan Liu *Department of Obstetrics and Gynecology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
Jie PengDepartment of Radiology, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.
Jinzhi LuDepartment of Laboratory Medicine, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osimertinib-induced severe lymphocytopenia can create a profound immunodeficiency state, facilitating opportunistic infections and progressive fibrotic lung disease. A 75-year-old female with EGFR-mutant NSCLC developed respiratory failure with diffuse ground-glass opacities and profound lymphocytopenia (ALC 0.48×10

Indexed as

AcrylamidesAniline CompoundsAntineoplastic AgentsCD4-Positive T-LymphocytesCytomegalovirus InfectionsPneumoniaPulmonary FibrosisAgedCarcinoma, Non-Small-Cell LungCytomegalovirusFemaleHumansIndolesLung NeoplasmsLymphocyte DepletionPyrimidinesAcrylamidesAniline CompoundsAntineoplastic AgentsIndolesosimertinibPyrimidinesCD4+ T-cellCMV pneumoniadiagnostic errordrug-induced lung injurylymphocytopeniaosimertinibpulmonary fibrosis

Identifiers

PMID41479888
PMCPMC12753373

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.